News - Bristol-Myers Squibb, GlaxoSmithKline

Filter

Popular Filters

Product launches to fuel lupus market growth

28-02-2014

The systemic lupus erythematosus (SLE) treatment market in the seven major countries (7MM) will increase…

Anti-Arthritics/RheumaticsBenlystaBristol-Myers SquibbEli LillyepratuzumabGlaxoSmithKlineGlobalImmuPharmaLupuzorMerck SeronoOrenciaPharmaceuticalRituxanRochetabalumabUCB

US patient share leaders in first-line BRAF-mutation positive malignant melanoma

27-11-2013

According to US oncologists surveyed in the third quarter of 2013 by BioTrends Research, a unit of Decision…

Bristol-Myers SquibbGlaxoSmithKlineMarkets & MarketingMekinistNorth AmericaOncologyPharmaceuticalRocheTafinlarYervoyZelboraf

EU5 rheumatologits rate Rituxan and Benlysta for Lupus

12-08-2013

Rheumatologists in the top European nations ( EU5) countries (France, Germany, Italy, Spain, UK) give…

Anti-Arthritics/RheumaticsBenlystaBiogen IdecBristol-Myers SquibbEuropeGlaxoSmithKlineMarkets & MarketingOrenciaPharmaceuticalRituxanRoche

Oncologists positive on Tafinlar, Mekinist and nivolumab for unresectable malignant melanoma

11-07-2013

US and European oncologists surveyed by health care advisory firm Decision Resources indicate that overall…

BiotechnologyBristol-Myers SquibbEuropeGlaxoSmithKlineMarkets & MarketingMekinistnivolumabNorth AmericaOncologyPharmaceuticalRocheTafinlarZelboraf

Lupus therapeutics boast blockbuster hopefuls as R&D continues, says GlobalData

24-06-2013

Lupus therapeutics are lacking, and patients with moderate forms of the disease are greatly underserved,…

BenlystaBiotechnologyBristol-Myers SquibbepratuzumabGlaxoSmithKlineImmunologicalsMarkets & MarketingOrenciaPharmaceuticalRare diseasesResearchUCB

Prognosis for renal cell carcinoma market development

27-11-2012

Through 2021, small-molecule angiogenesis inhibitors will dominate the renal cell carcinoma (RCC) drug…

Bristol-Myers SquibbGlaxoSmithKlineGlobalMarkets & MarketingnivolumabOncologyPfizerPharmaceuticalSutentVotrient

Top drugmakers set up non-profit TransCelerate to speed pharma R&D

20-09-2012

Some of the world's leading pharmaceutical companies have formed a non-profit organization to accelerate…

Abbott LaboratoriesAstraZenecaBiotechnologyBoehringer IngelheimBristol-Myers SquibbEli LillyGlaxoSmithKlineJohnson & JohnsonPfizerPharmaceuticalRegulationResearchRocheSanofiTransCelerate BioPharma

Yervoy and Zelboraf accounted for two-thirds of malignant melanoma drug market in 2011; report

18-09-2012

The launches of Bristol-Myers Squibb's (NYSE: BMY) immunotherapy Yervoy (ipilimumab) and Roche (ROG:…

Bristol-Myers SquibbdabrafenibGlaxoSmithKlineGlobalMarkets & MarketingOncologyPharmaceuticalRochetrametinibYervoyZelboraf

Pharma partnering dollars continue to decline, Burrill & Co reports

06-08-2012

The recent $3.4 billion partnering agreement announced in July between US pharma company Bristol-Myers…

AmylinAstraZenecaBiotechnologyBristol-Myers SquibbFinancialGlaxoSmithKlineHuman Genome SciencesLicensingMarkets & Marketing

Five more drug majors join NIH initiative to speed therapeutic discovery

13-06-2012

Five additional pharmaceutical companies have joined a US National Institutes of Health-led effort to…

Abbott LaboratoriesBristol-Myers SquibbGlaxoSmithKlineJohnson & JohnsonNorth AmericaPharmaceuticalResearchSanofi

Germany's IQWiG finds in favor of Yervoy but not Benlysta or Fampyra

09-05-2012

The German Institute for Quality and Efficiency in Health Care (IQWiG) in the past few days issued a…

BenlystaBiogen IdecBiotechnologyBristol-Myers SquibbEuropeFampyraGlaxoSmithKlineNeurologicalOncologyPharmaceuticalPricingRare diseasesRegulationYervoy

Back to top